Clinical trials · Tennessee
Advanced or Metastatic Solid Tumors clinical trials in Tennessee
We’re tracking 392 recruiting advanced or metastatic solid tumors studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07142304Recruiting
A study of compression gloves and boots to prevent chemo nerve damage
This trial is testing a wearable device (gloves and boots) that applies gentle compression to your hands and feet during chemotherapy. It aims to prevent or reduce nerve damage (numbness, tingling, pain) that some chemotherapy drugs can cause.
Nashville, TennesseeAges 18 years+ - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Germantown, TennesseeAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Nashville, TennesseeAges 18 years+ - NCT06095089RecruitingPhase 1
Study of two drugs for advanced prostate cancer
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Nashville, TennesseeAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Nashville, TennesseeAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Memphis, TennesseeAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Nashville, TennesseeAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Nashville, TennesseeAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Nashville, TennesseeAges 18 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Nashville, TennesseeAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Memphis, TennesseeAges 21 years+ - NCT06433011Recruiting
New clot-busting method for pulmonary embolism
This study tests a new way of delivering a clot-dissolving medicine for people with a serious but not immediately life-threatening pulmonary embolism. The goal is to see if giving the medicine as small bursts directly into the clot can help the heart recover faster.
Nashville, TennesseeAges Any age - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Chattanooga, TennesseeAges 18 years+ - NCT04485013RecruitingPhase 1
Study drug TTX-080 for advanced colorectal cancer
This Phase 1 study tests TTX-080, a drug designed to block a cancer immune “signal” (HLA-G) to help the body fight advanced colorectal cancer. It mainly checks safety and how the treatment works in people with cancer that has spread.
Nashville, TennesseeAges 18 years+ - NCT04792684Recruiting
Collecting colon samples from adults with colon findings
This study collects body samples to help evaluate tests for people with suspected or newly diagnosed colorectal conditions, often around the time of colonoscopy or surgery. Depending on the arm, you may be asked to have a colonoscopy soon or to provide samples before planned surgery.
Union City, TennesseeAges 45–84 - NCT05378347Recruiting
Compare two aortic stent graft types for AAA
This study compares two commercially used stent graft devices to treat an enlarged abdominal aorta (AAA). It aims to see which device works better and is safer over follow-up visits.
Memphis, TennesseeAges 20 years+ - NCT05422534RecruitingPhase 3
CoQ10 plus exercise for people with advanced kidney disease
This trial tests whether a supplement called CoQ10, along with supervised exercise, can improve how the body uses energy in people on chronic dialysis. It may help with muscle function and overall health if your heart and dialysis situation are stable enough.
Nashville, TennesseeAges 18–75 - NCT05433142RecruitingPhase 1
XmAb 819 for advanced kidney cancer and other solid tumors
This Phase 1 trial tests a new drug called XmAb 819 to treat advanced clear cell kidney cancer and other cancers that have grown despite standard treatments. It mainly looks at safety and how the body responds, with the goal of finding signs the drug can work.
Nashville, TennesseeAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Nashville, TennesseeAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Memphis, TennesseeAges 1–21 - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Collierville, TennesseeAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Nashville, TennesseeAges 18 years+ - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Memphis, TennesseeAges 1 month–21 years
Advanced or Metastatic Solid Tumors trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Vanderbilt University Medical Center · 8 studies
- Sarah Cannon Research Institute · 3 studies
- Tennessee Oncology · 3 studies
- Baptist Memorial Hospital and Cancer Center-Memphis · 2 studies
- Memphis VA Medical Center · 2 studies
- SCRI Oncology Partners · 2 studies
- St. Jude Children's Research Hospital · 2 studies
- Baptist Memorial Hospital and Cancer Center-Collierville
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in Tennessee?
- Yes. We're currently tracking 392 recruiting advanced or metastatic solid tumors studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.